In freshly isolated CAFs from patients with iCCA, Crenigacestat significantly (p < 0.001) inhibited Notch signaling, TGF-β1 secretion, and Smad-2 activation. This evidence concerns the gene SMAD2 and infantile convulsions and choreoathetosis.